Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IRMD Stock Summary
In the News
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
WINTER SPRINGS, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P.
5 Small Hidden Gems for the Rest of 2023
We have narrowed our search to five small-cap (market capital < $1 billion) stocks. These are: HCI, LMB, IRMD, GHM, MNTX.
4 Top Profitable Stocks to Invest in Using Net Income Ratio
NVIDIA (NVDA), iRadimed (IRMD), Perdoceo Education (PRDO) and Axcelis Technologies (ACLS) have been selected as the top picks with a high net income ratio.
Top 3 Profitable Stocks to Buy Now Using Net Income Ratio
iRadimed (IRMD), PulteGroup (PHM) and NVIDIA (NVDA) have been selected as the top picks with a high net income ratio.
IRADIMED CORPORATION to Participate at Upcoming Investor Conferences
WINTER SPRINGS, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences.
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
iRadimed (IRMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
3 Top Profitable Stocks to Invest in Using Net Income Ratio
Perdoceo Education (PRDO), Boot Barn (BOOT) and iRadimed (IRMD) have been selected as the top picks with a high net income ratio.
Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?
Want to start the week ahead of the pack? Check out ‘Momentum Mondays,' where I cover the leading breakout stocks in the market, summarize the major events of the week ahead, and prepare investors for profitable trading.
IRMD Financial details
IRMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.14 | 2.62 | 3.39 | 4.24 | 5.2 | |
Net income per share | 0.78 | 0.11 | 0.76 | 1.02 | 1.36 | |
Operating cash flow per share | 0.83 | 0.48 | 0.91 | 0.8 | 1.07 | |
Free cash flow per share | 0.79 | 0.43 | 0.85 | 0.65 | 0.43 | |
Cash per share | 3.77 | 4.29 | 5.06 | 4.61 | 3.95 | |
Book value per share | 4.52 | 5.06 | 5.85 | 5.86 | 5.67 | |
Tangible book value per share | 4.45 | 4.98 | 5.76 | 5.7 | 5.47 | |
Share holders equity per share | 4.52 | 5.06 | 5.85 | 5.86 | 5.67 | |
Interest debt per share | 0.24 | 0.22 | 0.2 | 0.22 | 0.16 | |
Market cap | 287.02M | 276.42M | 570.52M | 355.4M | 598.26M | |
Enterprise value | 246.5M | 229.06M | 511M | 299.65M | 550.54M | |
P/E ratio | 29.8 | 201.91 | 61.18 | 27.7 | 34.8 | |
Price to sales ratio | 7.45 | 8.72 | 13.64 | 6.67 | 9.13 | |
POCF ratio | 28.05 | 47.51 | 50.68 | 35.39 | 44.43 | |
PFCF ratio | 29.45 | 53.35 | 54.25 | 43.51 | 109.62 | |
P/B Ratio | 5.17 | 4.5 | 7.9 | 4.82 | 8.38 | |
PTB ratio | 5.17 | 4.5 | 7.9 | 4.82 | 8.38 | |
EV to sales | 6.4 | 7.22 | 12.22 | 5.62 | 8.4 | |
Enterprise value over EBITDA | 24.92 | 393.08 | 45.53 | 19.17 | 26.47 | |
EV to operating cash flow | 24.09 | 39.37 | 45.39 | 29.84 | 40.89 | |
EV to free cash flow | 25.29 | 44.21 | 48.59 | 36.69 | 100.87 | |
Earnings yield | 0.03 | 0 | 0.02 | 0.04 | 0.03 | |
Free cash flow yield | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | |
Debt to equity | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | |
Debt to assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | |
Net debt to EBITDA | -4.1 | -81.26 | -5.3 | -3.57 | -2.29 | |
Current ratio | 10.06 | 12.96 | 11.18 | 9.14 | 4.65 | |
Interest coverage | 0 | 0 | 0 | 26.86 | 0 | |
Income quality | 1.06 | 4.25 | 1.21 | 0.78 | 0.78 | |
Dividend Yield | 0 | 0 | 0 | 0.04 | 0.02 | |
Payout ratio | 0 | 0 | 0 | 0.98 | 0.77 | |
Sales general and administrative to revenue | 0.27 | 0.39 | 0.23 | 0.2 | 0.23 | |
Research and developement to revenue | 0.04 | 0.06 | 0.05 | 0.04 | 0.04 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | |
Capex to operating cash flow | -0.05 | -0.11 | -0.07 | -0.19 | -0.59 | |
Capex to revenue | -0.01 | -0.02 | -0.02 | -0.04 | -0.12 | |
Capex to depreciation | -0.39 | -0.48 | -0.53 | -2.8 | -10.46 | |
Stock based compensation to revenue | 0.05 | 0.12 | 0.03 | 0.03 | 0.03 | |
Graham number | 8.94 | 3.59 | 9.97 | 11.61 | 13.19 | |
ROIC | 0.15 | 0.03 | 0.12 | 0.16 | 0.21 | |
Return on tangible assets | 0.15 | 0.02 | 0.11 | 0.15 | 0.19 | |
Graham Net | 3.45 | 3.93 | 4.68 | 4.68 | 3.54 | |
Working capital | 53.1M | 58.82M | 69.42M | 69.64M | 59.67M | |
Tangible asset value | 54.66M | 60.42M | 71.06M | 71.6M | 68.9M | |
Net current asset value | 47.76M | 54.05M | 65.54M | 66.35M | 55.27M | |
Invested capital | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | |
Average receivables | 5.75M | 5.93M | 4.86M | 9.21M | 12.75M | |
Average payables | 883.11K | 825.4K | 719.98K | 1.29M | 1.83M | |
Average inventory | 3.85M | 3.79M | 4.12M | 4.83M | 9.1M | |
Days sales outstanding | 69.11 | 52.65 | 44.84 | 90.9 | 68.06 | |
Days payables outstanding | 41.14 | 29.45 | 29.26 | 54.63 | 44 | |
Days of inventory on hand | 150.77 | 176.34 | 160.73 | 163.03 | 303.8 | |
Receivables turnover | 5.28 | 6.93 | 8.14 | 4.02 | 5.36 | |
Payables turnover | 8.87 | 12.39 | 12.47 | 6.68 | 8.29 | |
Inventory turnover | 2.42 | 2.07 | 2.27 | 2.24 | 1.2 | |
ROE | 0.17 | 0.02 | 0.13 | 0.17 | 0.24 | |
Capex per share | -0.04 | -0.05 | -0.06 | -0.15 | -0.64 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.18 | 1.23 | 1.28 | 1.31 | 1.38 | |
Net income per share | 0.29 | 0.27 | 0.33 | 0.4 | 0.36 | |
Operating cash flow per share | 0.24 | 0.37 | 0.28 | 0.11 | 0.31 | |
Free cash flow per share | 0.2 | -0.15 | 0.25 | 0.08 | 0.26 | |
Cash per share | 4.61 | 3.4 | 3.64 | 3.71 | 3.94 | |
Book value per share | 5.86 | 5.11 | 5.48 | 5.92 | 5.66 | |
Tangible book value per share | 5.69 | 4.93 | 5.29 | 5.72 | 5.46 | |
Share holders equity per share | 5.86 | 5.11 | 5.48 | 5.92 | 5.66 | |
Interest debt per share | 0.14 | 0.16 | 0.18 | 0.17 | 0.19 | |
Market cap | 355.69M | 495.54M | 601.33M | 559.18M | 599.06M | |
Enterprise value | 299.93M | 455.11M | 557.76M | 514.58M | 551.35M | |
P/E ratio | 24.21 | 36.37 | 35.97 | 27.59 | 32.99 | |
Price to sales ratio | 23.93 | 32.02 | 37.28 | 33.88 | 34.33 | |
POCF ratio | 117.05 | 106.66 | 171.14 | 401.51 | 153.12 | |
PFCF ratio | 138.55 | -259.32 | 191.79 | 586.35 | 182.66 | |
P/B Ratio | 4.83 | 7.7 | 8.72 | 7.5 | 8.39 | |
PTB ratio | 4.83 | 7.7 | 8.72 | 7.5 | 8.39 | |
EV to sales | 20.18 | 29.41 | 34.58 | 31.18 | 31.59 | |
Enterprise value over EBITDA | 70.51 | 108.62 | 108.29 | 87.14 | 106.85 | |
EV to operating cash flow | 98.7 | 97.95 | 158.74 | 369.49 | 140.92 | |
EV to free cash flow | 116.83 | -238.16 | 177.89 | 539.58 | 168.11 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
Debt to equity | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | |
Debt to assets | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | |
Net debt to EBITDA | -13.11 | -9.65 | -8.46 | -7.55 | -9.25 | |
Current ratio | 9.14 | 9.07 | 8.71 | 9.13 | 4.65 | |
Interest coverage | -9.48 | -11.7 | 0 | 0 | 15.07 | |
Income quality | 0.83 | 1.36 | 0.84 | 0.27 | 0.86 | |
Dividend Yield | 0.04 | 0.03 | 0 | 0 | 0.02 | |
Payout ratio | 3.42 | 3.88 | 0 | 0 | 2.91 | |
Sales general and administrative to revenue | 0.18 | 0.25 | 0.22 | 0.22 | 0.24 | |
Research and developement to revenue | 0.04 | 0.05 | 0.06 | 0.03 | 0.04 | |
Intangibles to total assets | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
Capex to operating cash flow | -0.16 | -1.41 | -0.11 | -0.32 | -0.16 | |
Capex to revenue | -0.03 | -0.42 | -0.02 | -0.03 | -0.04 | |
Capex to depreciation | 0.68 | -35.92 | -2.02 | -2.31 | -3.08 | |
Stock based compensation to revenue | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | |
Graham number | 6.21 | 5.58 | 6.4 | 7.32 | 6.77 | |
ROIC | 0.04 | 0.05 | 0.05 | 0.06 | 0.05 | |
Return on tangible assets | 0.04 | 0.05 | 0.05 | 0.06 | 0.05 | |
Graham Net | 4.67 | 3.44 | 3.64 | 3.91 | 3.53 | |
Working capital | 69.64M | 54.54M | 58.51M | 64.05M | 59.67M | |
Tangible asset value | 71.6M | 62.13M | 66.64M | 72.11M | 68.9M | |
Net current asset value | 66.35M | 50.02M | 53.66M | 59.09M | 55.27M | |
Invested capital | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | |
Average receivables | 11.96M | 12.4M | 11.31M | 11.93M | 12.5M | |
Average payables | 1.38M | 1.78M | 2.15M | 2.67M | 2.32M | |
Average inventory | 5.31M | 5.84M | 7.36M | 10.04M | 12.24M | |
Days sales outstanding | 80.38 | 67.07 | 61.83 | 69.71 | 63.04 | |
Days payables outstanding | 44.45 | 42.11 | 58.24 | 68.3 | 41.38 | |
Days of inventory on hand | 132.64 | 151.35 | 192.03 | 286.34 | 285.67 | |
Receivables turnover | 1.12 | 1.34 | 1.46 | 1.29 | 1.43 | |
Payables turnover | 2.02 | 2.14 | 1.55 | 1.32 | 2.18 | |
Inventory turnover | 0.68 | 0.59 | 0.47 | 0.31 | 0.32 | |
ROE | 0.05 | 0.05 | 0.06 | 0.07 | 0.06 | |
Capex per share | -0.04 | -0.52 | -0.03 | -0.03 | -0.05 |
IRMD Frequently Asked Questions
What is IRadimed Corporation stock symbol ?
IRadimed Corporation is a US stock , located in Winter springs of Fl and trading under the symbol IRMD
What is IRadimed Corporation stock quote today ?
IRadimed Corporation stock price is $43.99 today.
Is IRadimed Corporation stock public?
Yes, IRadimed Corporation is a publicly traded company.